Myles Brookman
Ophthalmology · Long Beach, CANPI 1063874139
Payments from drug & device makers
Across 122 payments — averaging $38.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$1K
- Alcon$906
- Amgen$562
- AbbVie$456
- Ivantis, Inc$299
- Sun Pharmaceutical Industries Inc.$163
- plus $821 from 10 others
What the payments were for
- Consulting fees$1,45031%
- Food & beverage$3,20769%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 2 | $1,450 |
| Alcon | 23 | $906 |
| Amgen(2 entities) | 31 | $562 |
| AbbVie(2 entities) | 21 | $456 |
| Ivantis, Inc | 3 | $299 |
| Sun Pharmaceutical Industries Inc. | 6 | $163 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $159 |
| Dompe US, Inc. | 6 | $148 |
| Harrow Eye, LLC | 10 | $137 |
| Oyster Point Pharma, Inc. | 4 | $102 |
| Bausch & Lomb Americas Inc. | 3 | $69 |
| Sight Sciences, Inc. | 3 | $67 |
| Aerie Pharmaceuticals, Inc. | 3 | $52 |
| Novartis | 2 | $46 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$516
- Clareon$169
How this compares
$4,657 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 86 | $51,985 |
| Cyclosporine | 34 | $33,791 |
| XiidraLifitegrast | 32 | $29,750 |
| Prednisolone Acetate | 603 | $16,458 |
| RestasisCyclosporine | 17 | $15,340 |
| Alphagan PBrimonidine Tartrate | 40 | $13,058 |
| RhopressaNetarsudil Mesylate | 28 | $9,235 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 52 | $9,105 |
| Latanoprost | 660 | $8,494 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 466 | $7,174 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $7,152 |
| Brimonidine Tartrate | 168 | $7,002 |
| Ketorolac Tromethamine | 524 | $6,680 |
| MoxifloxacinMoxifloxacin Hcl | 306 | $5,302 |
| Travoprost | 37 | $5,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P | $456 | $80,384143 claims |
| Bausch & Lomb Americas Inc.Xiidra | $69 | $29,75032 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $52 | $16,38744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Julie GasperiniLong Beach$814K
- Carl HartmanLong Beach$716K
- Dan TranLong Beach$649K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.